You are here

Herbert Smith Freehills advises sponsors on Simcere Pharmaceutical’s HK$3.57 billion Hong Kong IPO / 史密夫斐尔律师事务所作为联席保荐人境外律师为先声药业35.7亿港元IPO提供法律服务

27 October 2020 | Asia
News

Share

Leading global law firm Herbert Smith Freehills has advised Morgan Stanley Asia Limited and China International Capital Corporation Hong Kong Securities Limited as joint sponsors of pharmaceutical manufacturer Simcere Pharmaceutical Group Limited’s mainboard listing on the Stock Exchange of Hong Kong.

Simcere Pharmaceutical is an innovation and R&D-driven pharmaceutical company, with a diverse product portfolio and leading positions in various therapeutic segments. The company has increased investment in R&D in recent years, and has three R&D centres in Nanjing, Shanghai and Boston.

Simcere Pharmaceutical raised approximately HK$3.57 billion (US$460.6 million), and listed on 27 October 2020. The offering attracted seven cornerstone investors that agreed to subscribe for approximately HK$1.473 billion (US$190 million).

"Innovative Chinese healthcare companies are capitalising on strong R&D capabilities and product portfolios with good market potential,” said Hong Kong partner Matt Emsley. “The rapid aging of the population and increasing demand for healthcare are accelerating growth in the sector."

“We are delighted to have advised Morgan Stanley and CICC on this IPO. Herbert Smith Freehills has a proven track record of advising high-profile healthcare listings. We congratulate Simcere Pharmaceutical on its IPO, and look forward to its continued success.”

Partners Matt and Siddhartha Sivaramakrishnan led the team advising the sponsors, assisted by registered foreign lawyers George Wu and Karen Liu, senior associate Maisie Ko, associates Stephanie Chan, Jaime Fong, Afra Li and Kaiwen Sun, and trainee Troy Song in Hong Kong office. Stanley Xie led a team from Herbert Smith Freehills Kewei joint operation, assisted by associate Sean Ji and paralegal Jessica Sun.

全球领先的律师事务所史密夫斐尔作为制药商先声药业联席保荐人摩根士丹利和中金公司的境外律师,为其在香港联交所主板上市提供法律服务。

先声药业是一家以创新和研发为驱动的制药公司,产品组合多样化,在多个治疗领域处于领先地位。该公司近年来加大了研发投入,在南京、上海和波士顿设有三个研发中心。

先声药业在首次公开募股中融资约35.7亿港元 (约合4.606亿美元),于2020年10月27日开始在香港联交所交易。此次上市吸引了7名基石投资者,同意认购约14.73亿港元(约合1.9亿美元)。

史密夫斐尔香港办公室合伙人艾迈修 (Matt Emsley) 表示:“创新的中国医疗保健公司正在充分运用其强大的研发能力和具有良好市场潜力的产品组合发挥优势。人口的快速老龄化和人们对医疗保健日益增长的需求正在加速该行业的快速发展。”

艾迈修表示:“我们很高兴为摩根士丹利和中金公司就此次IPO提供服务。史密夫斐尔在为备受瞩目的医疗保健公司上市提供法律服务方面保持着优良业绩。衷心祝贺先声药业成功上市,并期待其取得更大发展。“

合伙人艾迈修和Siddhartha Sivaramakrishnan率领律师团队为此次上市联席保荐人提供法律服务。主要团队成员包括香港办公室吴卓人 (Registered Foreign Lawyer)、高美诗 (Senior Associate)、陈颖瑜 (Associate)、方靖颐 (Associate)、刘晓韵 (Associate)、李宝卿 (Associate)、孙凯文 (Associate) 和宋肇屹 (Trainee)。科伟史密夫斐尔上海联营办公室为此次上市提供协助,由合伙人谢守德带领,季晓源 (Associate) 和孙菁 (Paralegal) 支持。
 

Key Contacts

Media Contact

For further information on this news article, please contact:

Sally Greig, Head of Communications, Asia

Hong Kong
Tel: 
+852 21014624

VIVIAN HUANG, COMMUNICATIONS MANAGER, CHINA

Beijing
Tel: 
+86 10 65355025